Key result
Ticlopidine inhibited platelet aggregation and adhesion in patients with diabetic retinopathy, with mean ADP-induced aggregation dropping to approximately 25% at 2 weeks.
Why the study?
Does Ticlopidine inhibit platelet function and alter hemorheological parameters in patients with diabetic retinopathy?
Does Ticlopidine inhibit platelet function and alter hemorheological parameters in patients with diabetic retinopathy?
Ticlopidine at 200 mg/day effectively inhibits platelet aggregation and adhesion in patients with diabetic retinopathy without significantly altering blood viscosity.
Answers are grounded in this paper and cite their sources.
May support ticlopidine for platelet inhibition in diabetic retinopathy; hypothesis-generating and should not change practice.
Recent interest has focused on the implication of platelet function in the development and inhibition of thrombogenesis. Ticlopidine is oral durg with a platelet inhibitory effect, being developed by PARCOR CO. in France.Six patients with diabetic retinopathy were given 200mg/day of Ticlopidine and were clinically studied on the effect of Ticlopidine.Significant inhibition of platelet function (platelet aggregation and adhesion) was observed.No significant effect was found in plasma viscosity, whole blood viscosity and maximum dynamic elastic modules G'm in blood clotting curve. One patient with retinopathy showed a clear sign of improvement.
No takes yet. Share an insight, caveat, or question.
OKABE et al. (1979) studied Diabetic retinopathy (n=6). Ticlopidine vs. Baseline was evaluated on Platelet function (platelet aggregation and adhesion). Ticlopidine inhibited platelet aggregation and adhesion in patients with diabetic retinopathy, with mean ADP-induced aggregation dropping to approximately 25% at 2 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: